Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

Abstract Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spal...

Full description

Bibliographic Details
Main Authors: Liping Ye, Chuyong Lin, Xi Wang, Qiji Li, Yue Li, Meng Wang, Zekun Zhao, Xianqiu Wu, Dongni Shi, Yunyun Xiao, Liangliang Ren, Yunting Jian, Meisongzhu Yang, Ruizhang Ou, Guangzheng Deng, Ying Ouyang, Xiangfu Chen, Jun Li, Libing Song
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:EMBO Molecular Medicine
Subjects:
breast cancer
ESR1
methylation
SALL2
tamoxifen resistance
Online Access:https://doi.org/10.15252/emmm.201910638

Internet

https://doi.org/10.15252/emmm.201910638

Similar Items